Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the sale, the chief operating officer now directly owns 129,690 shares of the company's stock, valued at approximately $998,613. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Daniel Lesueur also recently made the following trade(s):
- On Thursday, October 3rd, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12.
- On Wednesday, September 4th, Daniel Lesueur sold 8,137 shares of Health Catalyst stock. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46.
Health Catalyst Stock Performance
Shares of NASDAQ:HCAT opened at $8.86 on Friday. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The company's 50-day moving average is $8.01 and its 200 day moving average is $7.11. The company has a market capitalization of $535.76 million, a P/E ratio of -5.91 and a beta of 1.32.
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company | Ad
The AI boom is just getting started.
And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business had revenue of $75.90 million for the quarter, compared to analysts' expectations of $74.96 million. During the same period in the previous year, the business posted ($0.21) EPS. The firm's quarterly revenue was up 3.7% compared to the same quarter last year. As a group, research analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.
Institutional Investors Weigh In On Health Catalyst
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its stake in Health Catalyst by 14.7% in the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company's stock valued at $15,205,000 after acquiring an additional 305,079 shares during the period. Kennedy Capital Management LLC bought a new stake in shares of Health Catalyst during the first quarter valued at about $8,780,000. Acadian Asset Management LLC increased its position in shares of Health Catalyst by 38.3% during the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company's stock valued at $5,453,000 after buying an additional 200,494 shares during the period. ClariVest Asset Management LLC increased its position in shares of Health Catalyst by 303.9% during the first quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company's stock valued at $2,126,000 after buying an additional 212,425 shares during the period. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Health Catalyst during the third quarter valued at about $2,012,000. 85.00% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
HCAT has been the subject of several research reports. Piper Sandler reduced their price target on shares of Health Catalyst from $14.00 to $11.00 and set an "overweight" rating for the company in a research report on Monday, August 26th. Cantor Fitzgerald reissued an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. JPMorgan Chase & Co. lifted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Wednesday, September 4th. Stephens cut their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Thursday, August 8th. Finally, Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a report on Thursday. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.64.
Check Out Our Latest Research Report on HCAT
Health Catalyst Company Profile
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
